Clearance of total CT-DNA | Clearance of viable CT | |||||
n/N (%) | OR (95% CI) | aOR (95% CI) | n/N (%) | OR (95% CI) | aOR (95% CI) | |
Total | 32/531 (6.0) | 62/531 (11.7) | ||||
Diagnosis group | ||||||
(A) vCT and rCT | 3/155 (1.9) | 1*** | 1*** | 10/155 (6.5) | 1*** | 1*** |
(B) vCT (rCT not tested) | 21/351 (6.0) | 2.22 (0.95 to 10.98) | 3.35 (0.93 to 12.04) | 39/351 (11.1) | 1.81 (0.88 to 3.73) | 2.14 (0.99 to 4.62) |
(C) vCT (rCT negative) | 8/25 (32.0) | 23.84 (5.77 to 98.49) | 21.81 (4.94 to 96.27) | 13/25 (52.0) | 15.71 (5.70 to 43.26) | 15.63 (5.37 to 45.51) |
Years of age | ||||||
18–20 | 7/159 (4.4) | 1 | 1 | 9/159 (5.7) | 1* | 1* |
21–23 | 10/197 (5.1) | 1.16 (0.43 to 3.12) | 1.20 (0.43 to 3.37) | 28/197 (14.2) | 2.76 (1.26 to 6.04) | 2.79 (1.24 to 6.30) |
≥24 | 15/175 (8.6) | 2.04 (0.81 to 5.13) | 1.78 (0.66 to 4.78) | 25/175 (14.3) | 2.78 (1.26 to 6.15) | 2.47 (1.07 to 5.70) |
Days since initial CT diagnosis | ||||||
1–7 | 11/200 (5.5) | 1 | 1 | 22/200 (11.0) | 1 | 1 |
8–11 | 12/194 (6.2) | 1.13 (0.49 to 2.63) | 1.22 (0.50 to 2.97) | 21/194 (10.8) | 0.98 (0.52 to 1.85) | 0.97 (0.49 to 1.90) |
≥12 | 9/137 (6.6) | 1.21 (0.49 to 3.00) | 1.42 (0.52 to 3.91) | 19/137 (13.9) | 1.30 (0.68 to 2.51) | 1.31 (0.63 to 2.73) |
Study site (STI clinic) | ||||||
Limburg | 6/188 (3.2) | 1* | 1* | 17/188 (9.0) | 1 | 1 |
Rotterdam-Rijnmond | 17/160 (10.6) | 3.61 (1.39 to 9.38) | 3.71 (1.33 to 10.33) | 22/160 (13.8) | 1.60 (0.82 to 3.14) | 1.60 (0.77 to 3.22) |
Amsterdam | 9/183 (4.9) | 1.57 (0.55 to 4.50) | 1.78 (0.58 to 5.48) | 23/183 (12.6) | 1.45 (0.75 to 0.81) | 1.49 (0.71 to 3.10) |
Self-reported history of CT | ||||||
Yes | 15/151 (9.9) | 2.36 (1.44 to 4.85) | 1.55 (0.70 to 3.42) | 28/151 (18.5) | 2.32 (1.34 to 4.00) | 1.74 (0.96 to 3.15) |
No† | 17/380 (4.5) | 1** | 1 | 34/380 (8.9) | 1** | 1‡ |
Education | ||||||
Low | 16/195 (8.2) | 1 | na | 28/195 (14.4) | 1‡ | na |
Middle† | 8/197 (4.1) | 0.42 (0.17 to 1.02) | 20/197 (10.2) | 0.57 (0.29 to 1.12) | ||
High | 8/139 (5.8) | 0.77 (0.32 to 1.85) | 14/139 (10.1) | 1.13 (0.58 to 2.22) | ||
Background | ||||||
Western | 27/489 (5.5) | 1 | na | 54/489 (11.0) | 1 | na |
Non-Western | 5/42 (11.9) | 2.31 (0.84 to 6.36) | 8/42 (19.0) | 1.90 (0.83 to 4.31) | ||
No. of sex partners last 3 months | na | |||||
0 or 1 | 15/186 (8.1) | 1 | 21/186 (11.3) | 1 | na | |
2 or 3 | 13/257 (5.1) | 0.61 (0.28 to 1.31) | 29/57 (11.3) | 1.00 (0.55 to 1.84) | ||
≥4 | 4/88 (4.5) | 0.54 (0.18 to 1.69) | 12/88 (13.6) | 1.24 (0.58 to 2.65) |
Clearance of total CT-DNA: at follow-up, no total CT-DNA detected at the vaginal site; clearance of viable CT: at follow-up, no total CT-DNA or only non-viable CT at the vaginal site.
*Overall p value 0.01 to <0.05, **overall p value 0.001 to <0.01, ***overall p value <0.001.
†The few cases with unknown information are attributed to this category in analyses.
‡Overall p value 0.05 to <0.07.
This model includes diagnosisgroup, age, days since initial CT test (diagnosis), and study site (STI clinic);CI: Confidence interval; viability polymerase chain reaction (V-PCR) is used totest for viable CT; na: variable not entered into the multivariable model to calculateadjusted odds ratio.
aOR, OR in the multivariable analyses; CT, Chlamydia trachomatis; OR, odds ratio in univariable analyses; rCT, rectal Chlamydia trachomatis; vCT, vaginal Chlamydia trachomatis.